4.7 Article

Photothermal Therapy with HER2-Targeted Silver Nanoparticles Leading to Cancer Remission

Journal

PHARMACEUTICS
Volume 14, Issue 5, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14051013

Keywords

silver nanoparticles; photothermal therapy; local hyperthermia; targeted delivery; HER2; affibody; green synthesis; Ag

Funding

  1. Russian Science Foundation [17-7420146]
  2. Russian Foundation for Basic Research [20-04-60552, 20-34-90029, 19-515-06010]
  3. Israel Ministry of Science and Technology [3-16491]

Ask authors/readers for more resources

The study presents the promising use of silver nanoparticles with localized surface plasmon resonance (LSPR) phenomenon for targeted photothermal cancer therapy. These 35 nm HER2-targeted Ag NPs were synthesized using an aqueous extract of Lavandula angustifolia Mill, and demonstrated effective tumor treatment through hyperthermia after light irradiation. The Ag NPs were conjugated with affibody Z(HER2:342) polypeptide to target HER2-overexpressing cells, showing successful binding and internalization. Cytotoxicity assays showed effective cell death through reactive oxygen species production, and in vivo experiments resulted in complete tumor regression and prevention of metastasis.
Nanoparticles exhibiting the localized surface plasmon resonance (LSPR) phenomenon are promising tools for diagnostics and cancer treatment. Among widely used metal nanoparticles, silver nanoparticles (Ag NPs) possess the strongest light scattering and surface plasmon strength. However, the therapeutic potential of Ag NPs has until now been underestimated. Here we show targeted photothermal therapy of solid tumors with 35 nm HER2-targeted Ag NPs, which were produced by the green synthesis using an aqueous extract of Lavandula angustifolia Mill. Light irradiation tests demonstrated effective hyperthermic properties of these NPs, namely heating by 10 degrees C in 10 min. To mediate targeted cancer therapy, Ag NPs were conjugated to the scaffold polypeptide, affibody Z(HER2:342), which recognizes a clinically relevant oncomarker HER2. The conjugation was mediated by the PEG linker to obtain Ag-PEG-HER2 nanoparticles. Flow cytometry tests showed that Ag-PEG-HER2 particles successfully bind to HER2-overexpressing cells with a specificity comparable to that of full-size anti-HER2 IgGs. A confocal microscopy study showed efficient internalization of Ag-PEG-HER2 into cells in less than 2 h of incubation. Cytotoxicity assays demonstrated effective cell death upon exposure to Ag-PEG-HER2 and irradiation, caused by the production of reactive oxygen species. Xenograft tumor therapy with Ag-PEG-HER2 particles in vivo resulted in full primary tumor regression and the prevention of metastatic spread. Thus, for the first time, we have shown that HER2-directed plasmonic Ag nanoparticles are effective sensitizers for targeted photothermal oncotherapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available